BioNTech Heads to ASCO With Two-Shot Oncology Message as Cash Burn Tests Investor Patience

BioNTech presents key phase 2 data at ASCO amid falling revenue, heavy R&D spending, and a $19.6B cash pile; analyst targets range from $94 to $158.

BioNTech enters the American Society of Clinical Oncology meeting in Chicago with a clinical programme that spans bispecific antibodies, CTLA-4 blockade and antibody-drug conjugates – but the financial arithmetic behind the science is unsparing. In the first quarter of 2026, the company generated revenue of €118.1 million, down from €182.8 million a year earlier. It posted a net loss of €531.9 million while ploughing €557 million into research and development. Against that burn sits a cash pile of €16.76 billion (or roughly $19.6 billion, depending on the metric used), and a share buyback programme of up to $1.0 billion that runs through May 2027.

The stock, which changed hands at around €80 on the day of the primary disclosure, has lost 16.5% over the past month and trades nearly 21% below its 52-week high from October 2025. Analyst targets reflect the uncertainty: Canaccord retains a Buy rating with a $158 price target, while Leerink is more cautious at $94. The wide spread underscores how much the valuation now hinges on clinical execution.

The ASCO data readouts are the first major test of that narrative. On May 29, BioNTech presents phase 2 results for pumitamig, its bispecific antibody targeting both PD-L1 and VEGF-A. The data come from the ROSETTA-Lung-02 study in first-line non-small cell lung cancer, where pumitamig is being tested in combination with chemotherapy against the established Keytruda-plus-chemo standard. The study is a global phase 2/3 design, with the phase 3 portion already recruiting. Strong results would give the programme – and by extension BioNTech’s broader oncology pivot – serious credibility. Weak ones would feed doubts that the pipeline can deliver value quickly enough.

Pumitamig is not the only candidate in the spotlight. On May 30 the company unveils phase 2 data from the PRESERVE-004 study for gotistobart, a CTLA-4 antibody developed with OncoC4. The drug aims to deplete regulatory T cells within the tumour microenvironment. BioNTech describes the data as showing durable antitumour activity, clinically meaningful overall survival and a manageable safety profile in heavily pre-treated patients with platinum-resistant ovarian cancer.

Alongside these two key assets, BioNTech is showcasing three antibody-drug conjugate programmes: BNT326/YL202 (HER3-ADC) with a phase 1b/2 poster as monotherapy and in combination with pumitamig in advanced solid tumours; BNT324/DB-1311 (B7H3-ADC), where a phase 1/2a study is ongoing and a phase 3 in metastatic castration-resistant prostate cancer is planned for 2026; and trastuzumab pamirtecan (HER2-ADC) in a phase 3 comparison against chemotherapy for pre-treated HER2-expressing recurrent endometrial cancer. The ADC slate taps into a deal-making hot spot that pharma investors are watching closely.

In total, BioNTech now runs more than 25 phase 2 and phase 3 studies, including 13 pivotal trials across immunomodulators, ADCs and mRNA-based cancer immunotherapies. No regulatory approvals or commercial revenues have yet emerged from this pipeline. Management has guided for full-year 2026 revenue of €2.0–2.3 billion, while planning adjusted R&D spending of €2.2–2.5 billion. (An alternative company release cited revenue guidance of $2.3–2.6 billion, reflecting different currency conventions.) The company expects to have fifteen phase 3 trials active by year-end and is targeting seven late-stage oncology data points this year.

The ASCO presentations on May 29 (pumitamig) and May 30–June 1 (gotistobart and the ADCs) will need to demonstrate that the clinical evidence in ovarian, lung, prostate and endometrial cancers – as well as the broader solid-tumour programme – can support the thesis. Direct competition is forming: another bispecific PD-L1/VEGF-A candidate from the Pfizer-3SBio partnership is also due for an update at the meeting. For BioNTech, the margin for error in Chicago is thin. The next scheduled event after ASCO is the second-quarter earnings report, and until then the data will set the tone for the stock.